Abstract
Although pharmacology may be strictly viewed as the study of drugs (see, for example, the British Pharmacological Society Web site at http://www.bps.ac.uk/BPS.html), for many of us it also involves the use of drugs to study receptors. Indeed, the fundamental principle behind a pharmacological approach to the study of any biological system is that quantitative analysis of the effects of drugs on the responses of cells, tissues,or whole animals can provide useful information on the receptors involved. The approach is well-suited to situations where it is relatively easy to measure a response that is closely related to receptor activation, and although originally developed using isolated smooth-muscle preparations, platelets are also a very suitable system. Indeed, platelets have some advantages over smooth-muscle preparations in this respect, as the problem of diffusion of drugs through solid tissues is largely avoided in a suspension of cells. In addition, because in general each measurement is made on a separate sample of cells, there is no risk of desensitization due to repetitive addition of drugs to a single tissue, although obviously there may be time-dependent changes in the responses, which have to be taken into account. An important consideration is which response to measure: for platelets, one has the choice of overall functional responses such as shape change, aggregation, and the release of granule contents, which are more complex but may be of pathophysiological relevance, or of simpler biochemical responses such as changes in the levels of intracellular cyclic AMP or calcium. In theory any quantifiable response can be analyzed, although in some cases the results may differ depending on the response measured.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Clark, A. J. (1937) General pharmacology, in Heffter’s Handbuch der Experimentallen Pharmakologie (Clark, A. J., ed.), Vol. 4, Springer-Verlag, Berlin, pp. 1–223.
Leff, P. (1995) The 2-state model of receptor activation. Trends Pharmacol. Sci. 16, 89–97.
Bond, R. A., Leff, P., Johnson, T. D., Milano, C. A., Rockman, H. A., McMinn, T. R., et al. (1995) Physiological effects of inverse agonists in transgenic mice with myocardial over-expression of the beta(2)-adrenoceptor. Nature 374, 272–276.
Stephenson, R. P. (1956) A modification of receptor theory. Br. J. Pharmacol. 11, 379–393.
Furchgott, R. F. (1966) The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes, in Advances in Drug Research (Harper, N. J. and Simmonds, A. B.,eds.), Vol. 3, Academic Press, New York, pp. 21–55.
Black, J. W. and Leff, P. (1983) Operational models of pharmacological agonism. Proc. R. Soc. Lond. 220, 141–162.
Park, H. S. and Hourani, S. M. O. (1999) Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adenosine 5′-diphospbate (ADP) in human platelets. Br. J. Pharmacol. 127, 1359–1366.
Hall, D. A. and Hourani, S. M. O. (1993) Effects of analogs of adenine nucleotides on increases in intracellular calcium mediated by P2T-purinoceptors on human blood platelets. Br. J. Pharmacol. 108, 728–733.
Hourani, S. M. O. (2001) Discovery and recognition of purine receptor subtypes on platelets. Drug Devel. Res. 52, 140–149.
Palmer, R. K., Boyer, J. L., Schachter, J. B., Nicholas, R. A. and Harden, T. K. (1998) Agonist action of adenosine triphosphates at the human P2Y(1) receptor. Mol. Pharmacol. 54, 1118–1123.
Zhang, F. L., Luo, L., Gustafson, E., Lachowicz, J., Smith, M., Qiao, X. D., et al. (2001) ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J. Biol. Chem. 276, 8608–8615.
Uneyama, C., Uneyama, H., and Akaike, N. (1993) Cytoplasmic Ca2+ oscillation in rat megakaryocytes evoked by a novel type of purinoceptor. J. Physiol. 470, 731–749.
Somasundaram, B. and Mahaut-Smith, M. P. (1994) Three cation influx currents activated by purinergic receptor stimulation in rat megakaryocytes. J. Physiol. 480, 225–231.
Mahaut-Smith, M. P., Ennion, S. J., Rolf, M. G., and Evans, R. J. (2000) ADP is not an agonist at P2X1 receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br. J. Pharmacol. 131, 108–114.
Gaddum, J. H. (1937) The quantitative effects of antagonistic drugs. J. Physiol. 89, 7P–9P
Arunlakshana, O. and Schild, H. O. (1959) Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14, 48–58.
Kenakin, T. P. (1982) The Schild regression in the process of receptor classification. Can. J. Physiol. Pharmacol. 60, 249–265.
Hall, D. A. and Hourani, S. M. O. (1994) Effects of suramin on increases in cytosolic calcium and on inhibition of adenylate cyclase induced by adenosine 5′-diphosphate in human platelets. Biochem. Pharmacol. 47, 1013–1018.
Hourani, S. M. O., Hall, D. A., and Nieman, C. J. (1992) Effects of the P2-purinoceptor antagonist, suramin, on human platelet-aggregation induced by adenosine 5′-diphosphate. Br. J. Pharmacol. 105, 453–457.
Cusack, N. J. and Hourani, S. M. O. (1982) Adenosine 5′-diphosphate antagonists and human platelets — no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br. J. Pharmacol. 76, 221–227.
Gaddum, J. H. (1945) Lognormal distributions. Nature 156, 463–466.
Leff, P., Prentice, D. J., Giles, H., Martin, G. R., and Wood, J. (1990) Estimation of agonist affinity and efficacy by direct, operational model-fitting. J. Pharm. Methods 23, 225–237.
Prentice, D. J. and Hourani, S. M. O. (1997) Information in agonist curve shape for receptor classification, in Ann. N.Y. Acad. Sci., Vol. 812, pp. 234–235.
Cheng, Y. C. and Prusoff, W. H. (1973) Relationship between the inhibition constant (KI) and thc concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108.
Lazareno, S. and Birdsall, N. J. M. (1993) Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br. J. Pharmacol. 109, 1110–1119.
Kenakin, T. P. (1997) Pharmacologic Analysis of Drug-Receptor Interaction, 3rd ed., Raven Press, New York.
Kenakin, T. P. and Angus, J. A. (2000) The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems. Handbook of Experimental Pharmacology, 148, Springer-Verlag, Berlin Heidelberg.
Neubio, R.R., Spedding, M., Kenakin, T., and Christopoulos, A. (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII Update on Terms and Symbols in Quantitative Pharmacology. Pharmacol. Rev. 55, 597–606.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc.
About this protocol
Cite this protocol
Hourani, S.M.O. (2004). Pharmacological Approaches to Studying Platelet Function. In: Gibbins, J.M., Mahaut-Smith, M.P. (eds) Platelets and Megakaryocytes. Methods in Molecular Biology™, vol 273. Humana Press. https://doi.org/10.1385/1-59259-783-1:073
Download citation
DOI: https://doi.org/10.1385/1-59259-783-1:073
Publisher Name: Humana Press
Print ISBN: 978-1-58829-011-3
Online ISBN: 978-1-59259-783-3
eBook Packages: Springer Protocols